Infliximab may be cost effective in severe, treatment-resistant RA

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.480, 2005-01, pp. : 9-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Infliximab may be cost effective in severe, treatment-resistant RA

Inpharma, Vol. 1, Iss. 1493, 2005-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

The Cost Effectiveness of Infliximab for Severe Treatment-Resistant Rheumatoid Arthritis in the UK

By Barbieri Marco

PharmacoEconomics, Vol. 23, Iss. 6, 2005-01 ,pp. : 607-618

Adis International

Access to resources Recommend Favorite

Topical tacrolimus may be effective in paediatric patients with severe treatment-resistant Crohn's disease

Inpharma, Vol. 1, Iss. 1255, 2000-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Adalimumab more cost effective than infliximab in early RA

Inpharma, Vol. 1, Iss. 1499, 2005-01 ,pp. : 5-6

Adis International

Access to resources Recommend Favorite

Adalimumab more cost effective than infliximab in early RA

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 483, 2005-01 ,pp. : 3-4

Adis International

Access to resources Recommend Favorite